Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

PHASE3RecruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

August 15, 2026

Study Completion Date

February 15, 2027

Conditions

Acral Melanoma

Interventions

DRUG

camrelizumab+apatinib+TMZ

camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28

DRUG

camrelizumab+apatinib

camrelizumab 200mg，q2w+apatinib 250mg qd

DRUG

camrelizumab

camrelizumab 200mg，q2w

Trial Locations (1)

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Peking University Cancer Hospital & Institute

OTHER